Search for dissertations about: "viral hepatitis"
Showing result 16 - 20 of 90 swedish dissertations containing the words viral hepatitis.
-
16. Improving immunogenicity of hepatitis B and C viral proteins for vaccine design
Abstract : The hepatitis B and C virus (HBV, HCV) both presents a global health challenge, with an estimated 350 million individuals chronically infected with HBV and over 200 million infected with HCV. Reported cases of HBV and HCV have declined significantly due to screening of blood products and the availability of HBV vaccination. READ MORE
-
17. Hepatitis C virus kinetics during antiviral treatment
Abstract : It is estimated that 170 million individuals have chronic hepatitis C virus (HCV) infection, whereof 20-30% will develop end stage liver disease within 20-30 years. Antiviral therapy can stop this deterioration and clear the infection in 40-80% of the patients depending on treatment and HCV genotype. READ MORE
-
18. Design and Synthesis of Inhibitors Targeting the Hepatitis C Virus NS3 Protease : Focus on C-Terminal Acyl Sulfonamides
Abstract : Hepatitis C is a global health problem that affects approximately 120–180 million people. This viral infection causes serious liver diseases and the therapy available suffers from low efficiency and severe side effects. Consequently, there is a huge unmet medical need for new therapeutic agents to combat the hepatitis C virus (HCV). READ MORE
-
19. Prevention and treatment of hepatitis B virus infection
Abstract : Despite 25 years of effective vaccines and availability of treatment options for 15 years, hepatitis B virus (HBV) infections continue to be a major global health problem. In Sweden, selective screening and vaccination programmes are used in defined high-risk groups such as newborns of chronic HBV carrier mothers and health care workers with risk of blood exposure. READ MORE
-
20. Real-time PCR studies of genotypes, mutations and replication of hepatitis B virus
Abstract : Infection with hepatitis B virus (HBV) is an important cause of liver disease and affects 350 million people worldwide, causing 600,000 deaths/year. Treatment includes interferon and nucleoside analogues (NAs) such as lamivudine, entecavir, and tenofovir. READ MORE